Latest Novocure Limited Stories
ANAHEIM, Calif., Nov. 21, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston, presented follow-up results of a study focusing on overall survival in patients with recurrent glioblastoma multiforme (GBM). The long-term follow-up results from the Phase III EF-11 study compared overall survival at two and three years after initiating therapy in...
PORTSMOUTH, N. H., Nov. 17, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced the presentation of several studies evaluating the NovoTTF-100A System(TM) for the treatment of recurrent glioblastoma at the 16th Annual Scientific Meeting of the Society of NeuroOncology, November 17-20 in Anaheim, California. Data from the following studies will be presented at this meeting: Mitosis Interference of Cancer Cells during Anaphase by Electric Field from...
PORTSMOUTH, N.H., Oct. 5, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that Gabriel Leung has joined its board of directors. Mr. Leung will serve as vice chairman of the board of directors and chairman of the company's global commercialization team. Mr. Leung retired as executive vice president of OSI Pharmaceuticals and the President of OSI's Pharmaceuticals Business following the Astellas Pharma Inc. acquisition of OSI in 2010. Mr. Leung...
PORTSMOUTH, N.H., Aug. 4, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that it has entered into a long-term supply agreement with ITT Electronic Systems, a subsidiary of global engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ITT Electronic Systems supplies Novocure with the piezoelectric ceramic components used to manufacture the disposable electrodes for the NovoTTF-100A System, an FDA approved device indicated for the...
NEW YORK, April 15, 2011 /PRNewswire/ -- WFD Ventures, a venture capital firm focused on breakthrough medical products, announced the achievement of an important milestone for its portfolio company, NovoCure. The U.S. Food and Drug Administration (FDA) granted NovoCure approval to market its treatment for glioblastoma multiforme (GBM). WFD Ventures began working with NovoCure's founder, Dr. Yoram Palti, in 2003 and made its initial investment in 2004 to support the first-in-man clinical...
